Experimental pill promises new hope for deadly pancreatic cancer
In a 500-patient trial, the once-daily pill cut death risk by 60% and caused fewer severe side effects than chemotherapy, researchers said.
- On Sunday at the American Society for Clinical Oncology meeting in Chicago, researchers reported that the experimental pill daraxonrasib nearly doubled survival times for patients with advanced pancreatic cancer compared to chemotherapy.
- The drug targets the mutated KRAS gene, found in more than 90 per cent of pancreatic tumours, which continuously signals cancer cells to grow and was long considered 'undruggable' by researchers.
- In the 500-patient trial, daraxonrasib recipients lived a median of 13.2 months versus 6.7 months for chemotherapy patients, with severe side effects in 43.6 per cent of cases compared to 57.5 per cent on chemotherapy.
- Dr. Rachna Shroff of the Arizona Cancer Center called the results 'landscape-changing,' while the Food and Drug Administration plans to expedite review of the drug as a potential new standard of care.
- Researchers are now exploring whether daraxonrasib might shrink tumors to allow for surgery in earlier-stage patients, while the agency currently allows 'expanded access' to the experimental treatment for patients meeting specific criteria.
92 Articles
92 Articles
Why this new pill for a deadly cancer has doctors excited
A “gamechanger” new pill could double survival time in patients with the deadliest form of cancer, according to the results of a clinical trial. Pancreatic cancer is difficult to treat as it is often found late and more than half of patients are only diagnosed after it has spread. However, a new smart drug called Daraxonrasib could dramatically improve how long patients live after a diagnosis. How new pill could transform cancer treatment Daraxo…
U.S. researchers announced on Sunday that a new drug had made it possible to prolong the survival of people with advanced pancreatic cancer, raising the hope of finally seeing better treatments for one of the most deadly cancers.
Revolution Medicines’ RVMD Phase 3 daraxonrasib data in metastatic pancreatic cancer cut death risk 60% and doubled survival—see implications now.
Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. 'I actually started crying'
The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.
Coverage Details
Bias Distribution
- 44% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
